The study is being conducted to evaluate the safety, and efficacy of HRS-2129 for acute gouty arthritis. To explore the reasonable dosage of HRS-2129 for acute gouty arthritis.

Inclusion Criteria:

1. Able and willing to provide a written informed consent
2. Subjects requiring Acute gouty arthritis
3. Target joint VAS pain score ≥ 50 mm (screening)

Exclusion Criteria:

1. Subjects with a history of severe allergies
2. Subjects with nervous system disease
3. Subjects with a history of mental illness
4. Subjects with abnormal liver and renal function
5. Subjects with poorly controlled hypertensive
6. QTc：>450ms（male），>470ms（female）
7. History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)
8. The investigators determined that other conditions were inappropriate for participation in this clinical trial